What type of study is this?

This is a Quantitative Study study.

September 20, 2025

Epidemiological characteristics of lung cancer in China and worldwide.

Key Points

In 2022, global lung cancer incidence was 2.48 million and mortality was 1.82 million, reflecting notable gender disparities.
China's lung cancer incidence rate was 40.8 per 100,000, significantly higher than the global average, necessitating enhanced prevention strategies.
Elderly populations exhibited significantly higher lung cancer rates, indicating an urgent need for targeted interventions in older demographics.
Strong positive correlations were observed between human development index and lung cancer incidence and mortality rates.

Abstract

Objective: To analyze the current status and trends of lung cancer incidence and mortality in China and selected global regions, providing evidence for lung cancer prevention strategies in China. Methods: We extracted data from the GLOBOCAN 2022 database. Age-standardized Incidence rate (ASIR) and Age-standardized Mortality rate (ASMR) were calculated using Segi's world standard population. Epidemiological patterns were analyzed by region, age, sex, and human development index (HDI). Simple linear regression and Spearman's rank correlation coefficient were used to examine associations between HDI and ASIR/ASMR. Results: In 2022, global lung cancer incidence and mortality reached 2.48 million and 1.82 million cases respectively, with age-standardized rates of 23.6 per 100 000 (ASIR) and 16.8 per 100 000 (ASMR). Gender disparities were prominent, with male ASIR and ASMR being 2.0-fold and 2.5-fold higher than females. Elderly populations showed 11.6-fold higher ASIR and 14.4-fold higher ASMR compared to working-age adults. HDI demonstrated strong positive correlations with both ASIR (r=0.79, P＜0.001) and ASMR (r=0.74, P＜0.001). China accounted for 1.06 million new cases and 0.73 million deaths, with ASIR (40.8 per 100 000) and ASMR (26.7 per 100 000) exceeding global averages by 1.7-fold and 1.6-fold respectively. Chinese males showed 1.7-fold higher ASIR and 2.7-fold higher ASMR than females. Trend analysis revealed persistently high male incidence in China whereas rapidly increasing female rates, narrowing gender disparities. Projections estimate 1.80 million incident cases and 1.41 million deaths by 2050, representing 69.3% and 92.0% increases from 2022 levels. Conclusions: Significant heterogeneity exists in lung cancer burden across demographics and development levels, with strong HDI correlations. China bears disproportionate disease burden, necessitating intensified prevention efforts. These findings underscore the urgency of targeted interventions in high-risk populations.

Bookmark

Cite This Study

Ding et al. (Tue,) studied this question.

synapsesocial.com/papers/68d46abb31b076d99fa67f3c https://doi.org/https://doi.org/10.3760/cma.j.cn112152-20240905-00385

Bookmark